{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T02:26:16Z","timestamp":1784514376158,"version":"3.55.0"},"reference-count":18,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2012,7,10]],"date-time":"2012-07-10T00:00:00Z","timestamp":1341878400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2012,9]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Ulcerative colitis (<jats:styled-content style=\"fixed-case\">UC<\/jats:styled-content>) and <jats:styled-content style=\"fixed-case\">C<\/jats:styled-content>rohn's disease can sometimes relapse and be refractory to standard treatment following orthotopic liver transplantation (<jats:styled-content style=\"fixed-case\">OLT<\/jats:styled-content>) despite post\u2010transplantation immunosuppressive therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To evaluate the efficacy and safety of anti\u2010tumour necrosis factor (anti\u2010<jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content>) agents for the management of <jats:styled-content style=\"fixed-case\">IBD<\/jats:styled-content> following <jats:styled-content style=\"fixed-case\">OLT<\/jats:styled-content>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We reviewed the records of patients with a diagnosis of <jats:styled-content style=\"fixed-case\">IBD<\/jats:styled-content> who underwent <jats:styled-content style=\"fixed-case\">OLT<\/jats:styled-content> at <jats:styled-content style=\"fixed-case\">M<\/jats:styled-content>ayo <jats:styled-content style=\"fixed-case\">C<\/jats:styled-content>linic <jats:styled-content style=\"fixed-case\">R<\/jats:styled-content>ochester between 1985 and 2009. Patients were included if they had received anti\u2010<jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content> therapy post\u2010<jats:styled-content style=\"fixed-case\">OLT<\/jats:styled-content>. Clinical response was defined as a physician's assessment of improvement after 12\u00a0weeks of anti\u2010<jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content> usage, and mucosal healing was defined as the absence of ulcerations on follow\u2010up endoscopy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The median age of the eight study patients was 42.0\u00a0years and 37.5% were female patients. All had been diagnosed with <jats:styled-content style=\"fixed-case\">IBD<\/jats:styled-content> prior to <jats:styled-content style=\"fixed-case\">OLT<\/jats:styled-content> (<jats:styled-content style=\"fixed-case\">UC<\/jats:styled-content> in three and <jats:styled-content style=\"fixed-case\">C<\/jats:styled-content>rohn's disease in five). Indication for <jats:styled-content style=\"fixed-case\">OLT<\/jats:styled-content> was cirrhotic stage primary sclerosing cholangitis (<jats:styled-content style=\"fixed-case\">PSC<\/jats:styled-content>), and three concomitantly had cholangiocarcinoma. Clinical response was demonstrated in seven of eight patients (87.5%) and mucosal healing was demonstrated in three of seven (42.9%). Four infections (oral candidiasis, <jats:italic>\n<jats:styled-content style=\"fixed-case\">C<\/jats:styled-content>lostridium difficile<\/jats:italic> colitis, bacterial pneumonia and cryptosporidiosis) in three patients were reported. One patient developed an <jats:styled-content style=\"fixed-case\">E<\/jats:styled-content>pstein\u2013<jats:styled-content style=\"fixed-case\">B<\/jats:styled-content>arr virus\u2010positive post\u2010transplant lympho\u2010proliferative disorder. One death occurred due to complications from recurrent <jats:styled-content style=\"fixed-case\">PSC<\/jats:styled-content>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Starting Anti\u2010<jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content> therapy following <jats:styled-content style=\"fixed-case\">orthotopic liver transplantation<\/jats:styled-content> appears to be a potential option for <jats:styled-content style=\"fixed-case\">inflammatory bowel disease<\/jats:styled-content> management. Additional studies are needed, however, to confirm these findings and to further assess risks associated with this treatment strategy.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1365-2036.2012.05217.x","type":"journal-article","created":{"date-parts":[[2012,7,11]],"date-time":"2012-07-11T01:25:13Z","timestamp":1341969913000},"page":"569-574","source":"Crossref","is-referenced-by-count":54,"title":["Anti\u2010tumour necrosis factor treatment of inflammatory bowel disease in liver transplant recipients"],"prefix":"10.1111","volume":"36","author":[{"given":"A. B.","family":"Mohabbat","sequence":"first","affiliation":[{"name":"Department of Internal Medicine Mayo Clinic College of Medicine  Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. J.","family":"Sandborn","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology University of California San Diego  La Jolla CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"E. V.","family":"Loftus","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology Mayo Clinic College of Medicine  Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. H.","family":"Wiesner","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology Mayo Clinic College of Medicine  Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. H.","family":"Bruining","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology Mayo Clinic College of Medicine  Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,7,10]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(91)70019-T"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.43.5.639"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-200512000-00018"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.1800820836"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2006.01333.x"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08512-4"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030815"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050516"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.10.032"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2008.168"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2009.727"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0b013e3280116ccc"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2010.33"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2012.05141.x"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200008173430707"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.117762"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510290427"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/lt.21260"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2012.05217.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2012.05217.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T20:46:35Z","timestamp":1695501995000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2012.05217.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,10]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["10.1111\/j.1365-2036.2012.05217.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2012.05217.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,10]]}}}